Selank: How Strong Is the Evidence Behind Anxiety Claims?

Imagine reading two headlines: “Selank matched an anxiety medicine” and “Selank reduced treatment side effects.” Both sound encouraging. Yet one could describe Selank compared with another medicine, while the other describes adding Selank to a medicine already being taken. Those designs answer different questions—and both appear in the human research discussed here.^[1]^[2]

The strongest way to read an anxiety claim is to keep asking what was compared, what improved and how much the report lets us verify. This article uses the original abstracts of two clinical reports, not their full papers, alongside FDA information. It is a focused evidence review, not a claim to have located every Selank study.

Start with the comparison, not the headline

A treatment can be compared with placebo, an active medicine or the same background treatment without the added compound. The comparison determines the conclusion available. An add-on study cannot, by itself, show that the added treatment can replace the medicine used in both groups.

The 2008 Selank report compared Selank with medazepam in patients with generalized anxiety disorder and neurasthenia.^[1] The 2015 report compared phenazepam alone with phenazepam plus Selank in patients with anxiety-related disorders.^[2] Neither abstract describes a placebo comparison.^[1]^[2]

That does not make the studies worthless. Active-treatment comparisons can address practical clinical questions. It does mean that a sentence such as “Selank works for anxiety” has discarded much of the information needed to judge what the study actually found.

What the 2008 study reported

Zozulia and colleagues studied 62 patients: 30 receiving Selank and 32 receiving medazepam.^[1] They assessed patients using Hamilton, Zung and Clinical Global Impression scales, and also measured enkephalin activity in blood serum.^[1] The abstract reports similar anxiety-reducing effects for the two treatments, with additional antiasthenic and psychostimulant effects attributed to Selank.^[1] “Antiasthenic” refers to effects on weakness or fatigue-related symptoms; it does not automatically mean an improvement in every aspect of daily function.

These are encouraging author-reported findings. However, the abstract gives no numerical between-group symptom effect, confidence interval or formal equivalence margin.^[1] Describing effects as “similar” is therefore not enough, on this record, to conclude that Selank was proven equivalent to medazepam. Demonstrating equivalence requires more than failing to see an obvious difference.

The authors also reported relationships between an enkephalin-related laboratory measure and clinical symptoms, with changes during Selank treatment especially in generalized anxiety disorder.^[1] Those observations can inform biological hypotheses. They do not independently prove the mechanism responsible for symptom improvement, nor replace the need to understand the clinical comparison.

The 2015 result was about adding Selank

Medvedev and colleagues studied 70 patients: 30 receiving phenazepam alone and 40 receiving the combination of Selank and phenazepam.^[2] The abstract describes clinical assessments and several scales, including the UKU scale for tolerability, as well as attention-related testing and a quality-of-life questionnaire.^[2] It would be inaccurate to imply that the authors ignored tolerability.

They reported an earlier positive effect on the HDRS rating scale with combined treatment, along with fewer undesirable effects attributed to phenazepam.^[2] The reported improvements covered attention and memory impairment, asthenia, sedation, increased sleep duration, sexual disturbances, emotional indifference and orthostatism, or symptoms associated with standing upright.^[2] The authors described benefits during treatment and after tranquilizer withdrawal, and a positive impact on quality of life.^[2]

That conclusion deserves a fair hearing. Its scope is also clear: the authors argued for therapeutic possibilities involving Selank plus a benzodiazepine, not Selank monotherapy replacing one.^[2] The abstract does not provide numerical adverse-event rates, effect sizes or a specified duration of follow-up.^[2] It therefore cannot establish a universal claim of freedom from dependence, withdrawal problems or long-term harm.

Evidence	Main observation	Boundary to preserve
2008: Selank versus medazepam, 62 patients	Authors described similar anxiety-reducing effects.^[1]	An active comparison without a numerical equivalence analysis in the abstract.
2015: combination versus phenazepam alone, 70 patients	Authors reported earlier improvement and better tolerability with the combination.^[2]	Evidence about an add-on strategy, not Selank as a standalone replacement.
FDA entry for Selank acetate (TP-7)	Identifies specific safety questions to investigate.^[3]	A potential-risk assessment, not a quantified human adverse-event rate.

What the abstracts cannot settle

The available abstracts do not state enough about randomization, blinding, participant selection or follow-up to evaluate those features fully.^[1]^[2] Missing detail in an abstract is not proof that the investigators omitted a method. It is a limit on this review's access and on the certainty of conclusions drawn from it.

The 2008 abstract does not give a detailed adverse-event account; the 2015 abstract reports tolerability findings but does not provide the event counts needed to estimate their frequency.^[1]^[2] Neither abstract states the administration route, so this review does not attribute their results specifically to intranasal use or any other route.^[1]^[2]

These reports contain positive findings; they do not justify inventing a negative trial result. The unresolved questions concern how convincing, reproducible and transferable those findings are. Larger numbers, transparent methods and longer observation would help readers distinguish an encouraging signal from a dependable treatment claim.

Keep the compound, formulation and product separate

FDA's entry is specifically Selank acetate (TP-7), listed under bulk substances nominated but withdrawn.^[3] It says compounded drugs containing Selank acetate may pose immunogenicity risks for certain routes because of potential aggregation and peptide-related impurities, and that FDA lacks important human safety information.^[3] Immunogenicity is the potential to provoke an immune response. The entry does not quantify a human reaction rate or say that no human Selank studies exist. Its location alone establishes neither a universal ban nor every product's approval or compounding status.

Approved medicines, clinical-trial preparations, compounded products and research reagents are different evidence contexts. A research label or purity percentage cannot establish medicinal equivalence, microbiological quality, human exposure or suitability. This does not mean every research vial is contaminated or untested; it means those questions require their own evidence.

FDA's June 2026 Wholesale Peptide letter addressed Prostamax and Gonadorelin, not Selank.^[4] Its relevant general points concern research disclaimers alongside human-use claims, and injectable products bypassing defenses against toxins and microorganisms.^[4] It is not a Selank-specific finding.

Research materials should not be consumed or self-administered. The human literature deserves careful reading, including its reassuring observations, without turning a small comparative study or combination result into permission to self-treat anxiety.